Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 10/20 | 0.58 |
| ▸ | TP53 | P04637 | 8/20 | 0.58 |
| ▸ | RAD52 | P43351 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137444 | 0.89 | HTR6 (0.63) | HTR6SIRT6HTR2AMAPTALDH1A1 | |
| SCHEMBL3147476 | 0.80 | HTR6 (0.67) | HTR6SIRT6HTR2AMAPTGAA | |
| SCHEMBL3619818 | 0.78 | HTR6 (0.58) | HTR6HTR2AMAPTTP53RAD52 | |
| SCHEMBL15722449 | 0.77 | HTR6 (0.70) | HTR6SIRT6HTR2AMAPTGAA | |
| SCHEMBL2476652 | 0.77 | HTR6 (0.70) | HTR6SIRT6HTR2AMAPTGAA | |
| Hydrochloric Acid SCHEMBL3617007 | 0.77 | RAD52 (0.59) | HTR6HTR2ARAD52ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL3611439 | 0.77 | HTR6 (0.57) | HTR6HTR2AMAPTTP53RAD52 | |
| SCHEMBL3624218 | 0.76 | RAD52 (0.53) | HTR6HTR2AMAPTRAD52GAA | |
| SCHEMBL3613608 | 0.76 | MAPT (0.65) | HTR6SIRT6MAPTRAD52SMN1; SMN2 | |
| SCHEMBL3618341 | 0.76 | RAD52 (0.64) | HTR6HTR2ARAD52ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101142201-A | Substituted phenyl-piperazine compounds, their preparation and use in medicaments | ESTEVE LABOR DR (ES) | 2008-03-12 | — | — | CN | claimed |
| EP-1844031-A1 | SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-17 | — | — | EP | claimed |
| EP-1695971-A1 | Substituted phenyl-piperazine compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | claimed |
| WO-2006069807-A1 | SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | claimed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| CN-101563106-A | Combination of nmda- receptor ligand and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-10-21 | — | — | CN | disclosed |
| CN-101500611-A | Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-08-05 | — | — | CN | disclosed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | disclosed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | disclosed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | disclosed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | disclosed |
| CN-101142201-A | Substituted phenyl-piperazine compounds, their preparation and use in medicaments | ESTEVE LABOR DR (ES) | 2008-03-12 | — | — | CN | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| EP-1844031-A1 | SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-10-17 | — | — | EP | disclosed |
| EP-1695971-A1 | Substituted phenyl-piperazine compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006069807-A1 | SUBSTITUTED PHENYL-PIPERAZINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885SIRT6 446/4885HTR2A 16/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | HTR6 4/4885SIRT6 1315/4885HTR2A 23/4885 |
| US-20090042904-A1 | Substituted Phenly-Piperazine Compounds, Their Preparation And Use In Medicaments | HTR6, HTR5A, HTR7 | HTR6 1/4885SIRT6 270/4885HTR2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.